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                            False-positive results are an inherent feature of biomedical research. 
They are a source of inconsistent and misleading evidence and have 
potential impact on approaches to prevent and cure diseases and on 
the allocation of research resources. Some have argued that the 
majority of positive research findings are likely to be false, especially 
those based on large-throughput molecular approaches that involve 
many associations between “determinants” and “outcomes” (  1  ,  2  ). 
  Epidemiology is particularly prone to the generation of false-
positive results. Although epidemiological studies have been key to 
the identiﬁ  cation and quantiﬁ  cation of cancer risks that are associ-
ated with cigarette smoking, alcohol consumption, asbestos and 
other occupational exposures, radiation, infectious agents, medica-
tions, and other factors (  3  ), the reporting of associations that are 
not replicated is also a common occurrence in epidemiology. The 
problem is induced in part by the generation in many epidemio-
logical studies of large sets of results, which are usually in the form 
of associations between multiplicities of both risk and protective 
factors and health outcomes. The challenge of making inferences 
in the face of such multiple comparisons is often made more difﬁ  -
cult by the increasing use of multiple exposure metrics and baseline 
reference categories in calculating risk estimates. 
  Results relating to the primary a priori objectives of the study 
are often not the only data presented. In addition, “positive” or 
“statistically signiﬁ  cant” ﬁ  ndings from secondary analyses may be 
selectively reported as either generating new hypotheses or con-
ﬁ  rming ex post facto derived hypotheses. Further exacerbating the 
problem in epidemiological studies is the search for and reporting 
of weak associations, among which the potential for the distorting 
inﬂ  uences of bias, confounding, and chance is further enhanced. 
  Avoidance of false-positive results in epidemiology is desirable 
for many reasons. Such erroneous scientiﬁ  c evidence may lead to 
inappropriate governmental and public health decisions, including 
the introduction of costly and potentially harmful measures. The 
damage from erroneous ﬁ  ndings, however, extends beyond their 
immediate societal and ﬁ  nancial consequences and entails aspects 
such as loss of credibility of epidemiological results in the eyes of 
the public, waste of public resources, and misguided research 
objectives among epidemiologists themselves (  4  ). 
  Despite the potential impact of false-positive ﬁ  ndings, there 
have been few attempts to review the extent of false-positive results 
in nonexperimental epidemiological research and to offer some 
guidance for recognizing and avoiding them. Some systematic 
reviews have noted general inadequacies in the design, analysis, 
and reporting of epidemiological studies, including subgroup 
analyses and multiplicity of associations being explored, both of 
which increase the likelihood of false-positive results (  5  ). In the 
area of genetic epidemiology, the problem of false-positive results 
has received increasing attention (  1  ,  6    –    8  ) 
  In this commentary  ,   we describe examples of apparent false-
positive results  —  some chosen from environmental or occupational 
settings and others from cancer epidemiology in general. Although 
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these examples are not necessarily typical of all false-positive 
associations, they illustrate the problems inherent in the identiﬁ  ca-
tion of cancer hazards and the quantiﬁ  cation of level of risk. The 
failure to replicate initial positive ﬁ  ndings in subsequent research 
will be illustrated using cumulative meta-analyses based on a 
random-effects model (  9  ). We then suggest possible guidelines for 
the reduction of the false-positive problem, including a call for 
some degree of epistemological modesty when presenting initial 
observational ﬁ  ndings and a toning down by epidemiologists in 
their interpretation and presentation of positive results to the sci-
entiﬁ  c community as well as to the media and general public. 
    Examples of False-Positive Results in 
Environmental and Occupational 
Cancer Epidemiology 
  Early reports of an increased risk of cancer in a particular exposed 
group have led to the identification of several agents as human car-
cinogens (  3  ), but for many other agents the suspicion of a carcino-
genic effect has not been confirmed in subsequent studies. Because 
cancer epidemiology has great societal impact, and avoidance of 
false-positive reports in this field deserves particular attention, we 
have selected one example from environmental epidemiology and 
one example of a reported occupational cancer association. 
Obviously, considerations addressed in these examples are applica-
ble to other areas of epidemiological research as well. 
  The ﬁ  rst example is of an apparently strong positive result for a 
pollutant in the general environment that was initially suspected to 
give rise to cancer but for which such an association has not been 
conﬁ  rmed in subsequent studies. In 1993, a report of a case  –  control 
study nested in a New York City  –  based cohort (  10  ) showed an asso-
ciation between breast cancer risk and serum levels of 1,1-dichloro-
2,2-bis(  p  -chlorophenyl)ethylene (DDE), the major metabolite of 
1,1,1,-trichloro-2,2-bis(  p  -chlorophenyl)ethane (DDT      ), an organo-
chlorine pesticide that was used extensively until the early 1970s. The 
study involved 58 women who had been diagnosed with breast cancer 
within 6 months of entry in the prospective cohort study and 171 
control subjects from the same cohort, and it reported a relative risk 
of 3.7 (95% conﬁ  dence interval [CI] = 1.0 to 13.5) for the highest vs 
lowest 20% of the DDE distribution in serum. This study was 
prompted by earlier results of small (<50 case patients) case  –  control 
studies (  11    –    14  ) that had suggested a modest association between 
breast cancer and exposure to DDE and polychlorinated biphenyls. 
An editorial accompanying the report of the New York City study 
(  15  ) stated that these ﬁ  ndings may have “extraordinary implications 
for the prevention of breast cancer” and that this study should “serve 
as a wake-up call for further urgent research.” 
  Accordingly, a series of studies were subsequently launched, 
including a large case  –  control study of breast cancer in Long 
Island, NY (  16  ), but they failed to replicate the earlier ﬁ  ndings. 
The results on serum DDE level from the prospective studies, 
including an expanded analysis of women who had been included 
in the original study from New York City and a combined analysis 
of ﬁ  ve prospective studies, were published between 1994 and 2001 
(  17    –    28  ) (  Table 1  ). We performed a cumulative meta-analysis of 
the initial study and seven subsequent studies published in 1994  –
  2000 (  Figure 1  ). The ﬁ  nal pooled estimate of the relative risk of 
breast cancer for the highest vs lowest DDE category was 0.95 
(95% CI = 0.7 to 1.3).                 
  The reason for the positive ﬁ  ndings in the original New York 
City study is unknown. Chance, which is still an underappreciated 
problem in our ﬁ  eld, seems likely. The short time that elapsed 
between blood collection and diagnosis of breast cancer may be 
another explanation because organochlorine compounds are stored 
in fat tissue, whose metabolism may be affected by the neoplastic 
process itself (  29  ). Overinterpretation and an apparent lack of 
skepticism had major roles in the wide acceptance of the result. 
Although the relative risk estimate of breast cancer among women 
  Table 1  .         Results of prospective studies on serum 1,1-dichloro-2,2-bis(  p  -chlorophenyl)ethylene level and risk of breast cancer  *     
    Reference Population
Period of 
blood 
collection
Follow-up, 
years
No. of case 
patients/control 
subjects
DDE level, 
reference 
category    †   
DDE level, 
highest 
category    †   
RR highest 
category (95% CI)   P    trend     
    10 Volunteers, 
  New York City
1985  –  1991 0.1  –  0.5 58/171 0.5  –  3.2 ppb 11.9  –  44.3 ppb 3.68 (1.01 to 13.5) 0.03 
  17 Health Maintenance 
 Organization  members, 
 California     
1964  –  1969 Mean 14.2 150/150 5.3  –  29.6 ppb 49.7  –  149.5 ppb 1.33 (0.68 to 2.62) 0.4 
  18 Volunteers, 
 Copenhagen
1976 0.1  –  17.0 240/477 NA    ‡   NA    ‡    0.88 (0.56 to 1.37) 0.5 
  21 Volunteers, Maryland 1974 1  –  20 346/346 <1017 ng/g 2447  –  10796 ng/g 0.73 (0.40 to 13.2) 0.1 
  22 Volunteers, Missouri 1977  –  1987 Mean 9.5 105/208 31  –  1377 ng/g 3501  –  20667 ng/g 0.8 (0.4 to 1.5) 0.7 
  24 Volunteers, 
  New York City
1985  –  1991 0.5  –  9.0 148/295 <664 ng/g >1934 ng/g 1.30 (0.51 to 3.35) 1.0 
  25 Blood donors, 
 Norway
1973  –  1991 Mean 8.8 150/150 NA  § NA  § 1.2  (NA) NA 
  20, 27 Nurses, United States 1989  –  1990 1.5  –  5.5 372/372 70  –  427 ng/g 955  –  1441 ng/g 0.82 (0.49 to 1.37) 0.1   
    *     DDE = 1,1-dichloro-2,2-bis(  p  -chlorophenyl)ethylene; RR = relative risk; CI = confidence interval; HMO = health maintenance organization; NA = not available.   
      †       DDE serum levels are either not lipid adjusted (expressed as parts per billion [ppb], equivalent to milligrams per gram serum) or lipid adjusted 
(expressed as nanograms per gram lipid).   
      ‡       Mean level, control subjects: 10.2 ppb; case patients: 9.9 ppb.   
    §     Mean level, control subjects: 1260 ng/g; case patients: 1230 ng/g.     990   Commentary | JNCI  Vol. 100, Issue 14  |  July 16, 2008
in the highest quintile of serum DDE compared with the lowest 
was almost 4.0, the width of the conﬁ   dence interval and the 
marginal level of statistical signiﬁ  cance should have tempered the 
enthusiasm for the ﬁ  nding. Similarly, a recently reported relative 
risk estimate of 5.0 (95% CI = 1.7 to 14.8) for serum levels of   p  ,  p  ’-
DDT and breast cancer risk, based on subgroup analyses in a 
nested case  –  control study (  30  ), also warrants a cautious interpreta-
tion. What is of ongoing concern is that given the history of stud-
ies of this exposure  –  disease issue, the results were still interpreted 
with few reservations and little if any caution. 
  A second example relates to the results of occupational cohort 
studies of lung cancer risk among workers who were exposed to 
acrylonitrile. Acrylonitrile is a chemical used in the manufacture 
of acrylic ﬁ  bers, resins, and nitrile rubber, as an intermediate in 
the chemical industry and, in the past, as a fumigant. The ﬁ  rst 
study of lung cancer mortality among workers who were exposed 
to acrylonitrile in a textile factory in the United States, which was 
reported in 1978 (  31  ), showed a fourfold increased risk, based on 
six deaths from lung cancer. An International Agency for 
Research on Cancer (IARC) working group cited this study in its 
review of acrylonitrile in 1979 and concluded that “while conﬁ  r-
matory evidence in experimental animals and humans is desir-
able, acrylonitrile should be regarded as if it were carcinogenic to 
humans” (  32  ). Following the initial report, a total of 16 partially 
overlapping occupational cohort studies have provided results on 
lung cancer risk among acrylonitrile-exposed workers, including 
an expanded analysis of the ﬁ  rst study, which identiﬁ  ed two addi-
tional observed and 2.9 additional expected lung cancer deaths 
(  33  ) (  Table 2  ).       
  When we performed a cumulative meta-analysis of the initial 
1978 ﬁ  ndings and of 15 subsequent studies of acrylonitrile and 
lung cancer that were published in 1980  –  1998, we found a steady 
decrease over time in the reported overall relative risk estimate of 
lung cancer in acrylonitrile workers (  Figure 2  ). The ﬁ  nal pooled 
estimate of the relative risk of lung cancer among the workers 
was 1.1 (95% CI = 0.9 to 1.4). This approach admittedly repre-
sents an overly simpliﬁ  ed review because, for the sake of compa-
rability, we restricted the meta-analysis to historical cohort 
studies and did not consider case  –  control studies [eg, Scélo et al. 
(  48  )] that may provide additional relevant information, we did 
not consider the results of internal (eg, dose  –  response) analyses 
available for several cohorts, and we did not consider the 
evidence for or against bias and confounding in each of the stud-
ies. However, the declining trend in the summary relative risk 
estimate as further data accumulated provides evidence that the 
initial ﬁ  nding was a false-positive result. In an updated review of 
the evidence in 1999, an IARC working group modiﬁ  ed the clas-
siﬁ  cation for acrylonitrile from “2A (probable carcinogen)” to 
“2B (possible carcinogen)” (  49  ).       
  Similar examples of false-positive results are relevant to the 
evidence linking exposure to established occupational carcinogens 
with cancer of organs that are not the primary target of their car-
cinogenic effect. A detailed analysis of results on other suspected 
occupational carcinogens is beyond the scope of this commentary, 
but for several agents it would show the same pattern seen for lung 
cancer among workers who were exposed to acrylonitrile, that is, 
  Table 2  .         Results of cohort studies on lung cancer risk among 
workers who were exposed to acrylonitrile  *     
    Reference
Overlap with previous 
studies,    †     reference N RR (95% CI)   
    31 None 6 4.0 (1.7 to 7.9) 
  34 None 6 0.86 (0.37 to 1.7) 
  33 31 2 0.69 (0.12 to 2.2) 
  35 None 11 2.0 (1.1 to 3.3) 
  36 None 1 2.0 (0.1 to 9.5) 
  37 None 9 1.2 (0.62 to 2.1) 
  38 None 9 1.5 (0.8 to 2.7) 
  39 31, 33 6 0.83 (0.36 to 1.6) 
  40 31, 33, 39 5 0.72 (0.29 to 1.5) 
  41 None 15 1.0 (0.62 to 1.54) 
  42 None 16 0.82 (0.51 to 1.2) 
  43 None 2 0.77 (0.14 to 2.4) 
  44 41 119 1.23 (1.05 to 1.43) 
  45 31, 33, 39, 40 27 0.69 (0.49 to 0.95) 
  46 42 31 1.33 (0.90 to 1.89) 
  47 37 44 1.0 (0.77 to 1.29)   
    *     N = number of observed lung cancer deaths; RR = relative risk; 
CI = confidence interval.   
      †       For studies overlapping with previous reports, only the additional observed 
lung cancers are reported (and the relative risk is based on these additional 
cancers only).     
      Figure 1    .       Cumulative meta-analysis of cohort stud-
ies of breast cancer and serum level of 1,1-dichloro-
2,2-bis(  p  -chlorophenyl) ethylene (highest vs lowest 
category in each study). Estimated relative risks 
(RRs) are shown with 95% conﬁ  dence  intervals 
(CIs) (  error bars  ) by year of publication of subse-
quent reports. In parentheses are references of 
studies included in the cumulative meta-analyses 
(see   Table 1   for details). Upper conﬁ  dence limit for 
the initial RR was 13.5.       
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early positive results were not conﬁ  rmed, or were shown to be less 
strong, in subsequent studies.   
    Sources of False-Positive Results 
  The issue of multiplicity of exposures and outcomes, and conse-
quent multiple comparisons and subgroup analyses leading to many 
“statistically significant” (yet false) findings arising by chance, is 
likely the major contributor to false-positive findings in epidemiol-
ogy. Epidemiological studies, whether cross-sectional, case  – 
control, or cohort in design, tend to obtain information on multiple 
exposures and disease outcomes, so the possibility often exists for 
examining hundreds or thousands of exposure  –  disease combina-
tions. A similar situation arises in emerging genetic epidemiological 
studies in which even larger numbers of traits, up to tens or hun-
dreds of thousands of variants, can be examined. In a quantitative 
approach to this problem, Ioannidis et al. (  8  ) reviewed 36 genetic 
disease associations and found that for 25 of them, the first report 
gave a stronger estimate of genetic association than did subsequent 
studies; in 10 of these associations, the difference between the first 
and the subsequent results was statistically significant. The same 
authors subsequently considered the results of 55 meta-analyses 
(  50  ), including 579 study comparisons of genetic associations, and 
found that for each association the largest study generally yielded 
more conservative results than the meta-analysis, that in 26% of the 
meta-analyses the association was statistically significantly stronger 
in the first study, and that in only 16% was the genetic association 
found in the first study replicated without evidence of heterogene-
ity and bias. Statistical techniques aimed at reducing the likelihood 
of false-positive associations, such as false discovery rate ( 51  ,  52  ), false-
positive report probability (  53  ), and Bayesian false discovery proba-
bility (  54  ), are now included in the analysis of databases with large 
numbers of genetic variants [eg, Wellcome Trust Case Control 
Consortium (  55  )]. It seems appropriate that similar approaches be 
applied in other areas of cancer epidemiology that are prone to 
reporting false-positive results, including studies of potential occu-
pational and environmental carcinogens. 
  There are multiple reasons besides chance why positive results, 
particularly initial results, in epidemiological studies may be false 
(  2  ,  56  ). To formally address the determinants of false-positive 
      Figure 2    .        Cumulative meta-analysis of cohort 
studies of lung cancer and occupational expo-
sure to acrylonitrile. Estimated relative risks 
(RRs) are shown with 95% conﬁ  dence intervals 
(CIs) (  error bars  ) by year of publication of subse-
quent reports. In parentheses are references of 
studies included in the cumulative meta-analyses 
(see   Table 2   for details).       
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results in occupational cancer, Swaen et al. (  57  ) scored the main 
characteristics of studies reporting a positive association with 
established target (true positive) and nontarget (false positive) 
organs of 19 occupational carcinogens. The main determinants of 
false-positive ﬁ   ndings were the absence of a speciﬁ  c  a  priori 
hypothesis, a small magnitude of the association, the absence of a 
dose  –  effect relationship, and the lack of adjustment for tobacco 
smoking. Although this analysis can be criticized because of sub-
jective aspects in the deﬁ  nition of target organs and in quality 
scoring, it highlights the important roles of confounding and bias, 
together with chance, in the generation of false-positive results. 
  Although chance is a major cause of false-positive results, it is 
less appreciated that false leads may also be generated by bias. Bias 
consists of a systematic alteration of the research ﬁ  ndings  due 
to factors related to study design, data acquisition, analysis, or 
reporting of results. There is a fundamental distinction between 
false-positive results that are generated by chance and those caused 
by bias  —  the former will rarely be replicated in subsequent investi-
gations, whereas bias may operate in a similar fashion in different 
settings and populations and thus will provide a consistent pattern 
of independently generated results. Even if only a relatively low 
proportion of results are generated by bias, the probability of false-
positive discovery may be substantial. 
  Information bias, or recall bias, is a likely source of false-posi-
tive ﬁ   ndings. Early studies examining a possible association 
between induced abortion and breast cancer risk that were based 
on retrospectively ascertained information generated evidence 
indicating that women who had undergone an induced abortion 
were at increased risk of breast cancer (  58  ). A collaborative reanal-
ysis of data from 53 epidemiological studies comparing women 
with prospectively ascertained records of one or more induced 
abortions vs women with no such record (  59  ) reported a relative 
risk of breast cancer equal to 0.93 (95% CI = 0.89 to 0.96). It is 
now apparent that information bias had a major role in generating 
the early false-positive results. Control women were less likely to 
report their previous induced abortions than were women with 
breast cancer (  58  ,  60  ). In general, patients have greater motivation 
(eg, to explain their disease) and thus are more likely to remember 
and/or report certain past exposures than are healthy individuals 
who are selected as control subjects. 992   Commentary | JNCI  Vol. 100, Issue 14  |  July 16, 2008
  Another source of false-positive ﬁ  ndings is selection bias. A 
likely example of selection bias is the 1981 report of increased 
pancreatic cancer risk associated with coffee consumption in one of 
the earliest epidemiological studies of this disease (  61  ). Many 
investigators aimed to replicate these ﬁ  ndings, but the results of 
subsequent studies were in general null and by the end of the 1980s 
a causal association between coffee drinking and pancreatic cancer 
was considered unlikely (  62  ,  63  ). Yet for several years the suspicion 
that coffee drinking was associated with a highly lethal cancer was 
widespread in the medical community and the general public. This 
false-positive result was generated, at least in part, by exclusions 
from the control patient population, but not from the case patients, 
of individuals with a history of diseases related to cigarette smok-
ing and alcohol consumption; because these exposures were highly 
correlated with coffee consumption, the exclusions likely led to a 
deﬁ  cit of coffee consumers in the control group. 
  Another source of bias and false-positive ﬁ  ndings in observa-
tional studies is confounding resulting either from incomplete sta-
tistical adjustment for measured variables or from the inability to 
adjust for unmeasured distorting variables. For example, results of 
early epidemiological studies showed an increased risk of cervical 
cancer among women who were infected with agents such as her-
pes simplex virus 2 and chlamydia. When sensitive and speciﬁ  c 
markers of infection with human papilloma virus became available, 
however, it was clear that the early positive results for the other 
sexually transmitted agents were due to confounding by human 
papilloma virus (  64  ). Although the importance of residual con-
founding and unmeasured confounders as a source of bias in epi-
demiological studies has been downplayed by many (  65  ), a recent 
statistical simulation study (  66  ) showed that with plausible assump-
tions, effect sizes on the order of 1.5  –  2.0, which is a magnitude 
frequently reported in epidemiology studies, can be generated by 
residual and/or unmeasured confounding. The real effect of 
unmeasured confounders is of course unknown but may explain 
some of the notorious differences between well-known cohort 
studies and subsequent randomized trials. 
  The randomized controlled trial is often presented as the gold 
standard of epidemiological studies, with the random assignment 
of treatments mitigating against the potential inﬂ  uences of bias 
and confounding. Systematic reviews have found evidence of 
higher relative risks in observational studies as compared with ran-
domized controlled trials addressing the same question (  67  ,  68  ). 
However, even randomized controlled studies are not exempt from 
reporting of false-positive results that arise by chance. In a review 
of 39 highly cited (deﬁ  ned as studies cited 1000 or more times in 
the literature) randomized controlled trials that reported an origi-
nal claim of an effect (  69  ), the results of 19 were replicated by sub-
sequent studies, whereas for nine trials subsequent results either 
contradicted the ﬁ  ndings of the original report or provided evi-
dence of a weaker effect (the remaining 11 trials did not have sub-
sequent attempts of replication). Small size of the original study 
was the strongest predictor of subsequent refutation. Premature 
conclusions can be avoided by cautious interpretation of initial tri-
als, especially when they are small, and by trial registration, which 
is a requirement of the International Committee of Medical 
Journal Editors (  70  ). Moreover, there is an unfortunate tendency 
to highlight “positive” or “statistically signiﬁ  cant” ﬁ  ndings in the 
abstracts of both observational studies and randomized trials, even 
when the results are doubtful or open to criticism (  71  ).   
    Publication Bias 
  Another cause of false-positive reporting in cancer epidemiology is 
publication or reporting bias. It originates from the tendency of 
authors and journal reviewers and editors to report and publish 
“positive” or “statistically significant” results over “null” or “non  –
  statistically significant” results, particularly if the findings appear to 
confirm a previously reported association (ie, the “bandwagon 
effect”). As with other forms of bias, preferential publication gener-
ates a false sense of consistency among studies. Statistical tests have 
been proposed to assess the presence of publication bias (  72    –    75  ); 
unfortunately, these tests tend to have low power and require a 
large number of independent studies to provide evidence of bias. 
There are, however, suspected occupational and environmental 
carcinogens for which a sufficiently large number of studies are 
available to allow testing for publication bias. 
  One group of suspected environmental carcinogens is the poly-
chlorinated dibenzo-para-dioxins, which are by-products of the 
manufacture of chlorophenols and chlorophenoxy herbicides; they 
are also produced during incineration of organic material and in 
other thermal processes, such as metal processing and paper pulp 
bleaching. The most toxic is 2,3,7,8-tetrachlorodibenzo-  p  -dioxin 
(2,3,7,8-TCDD), which has been found to cause tumors in rodents 
under certain conditions (  62  ). Concern about the carcinogenicity 
of dioxins in general, and 2,3,7,8-TCDD in particular, has led to 
epidemiological studies that are both occupationally based (eg, 
workers in the chemical industry, pesticide applicators) and com-
munity based (eg, residents in contaminated areas, the general 
population). Non-Hodgkin lymphoma (NHL) has been among 
the suspected targets of dioxin carcinogenicity in humans. At the 
time of the most recent IARC Monograph evaluation (  76  ), results 
on NHL risk were available from 16 studies of 2,3,7,8-TCDD  –
  exposed populations  —  eight cohort studies and eight case  –  control 
studies (  76  ). Although a meta-analysis suggests an increased risk of 
NHL in these populations (meta-relative risk = 1.6, 95% CI = 1.2 
to 2.1), there is evidence of publication bias [  Figure 3  ;   P   = .02, 
Begg test (  75  )]. In the absence of publication bias, the results of 
individual studies plotted against their precision, as in   Figure 3  , 
should be distributed in a triangular (“funnel”) pattern, with less 
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  Figure 3    .       Funnel plot of results of studies on dioxin exposure and risk 
of non-Hodgkin lymphoma.   Closed diamonds  , cohort studies;   empty 
diamonds  , case  –  control studies. RR = relative risk. se = standard error. 
See (76) for detailed results.       jnci.oxfordjournals.org    JNCI | Commentary 993
precise studies (on the right side of the graph) randomly dispersed 
around the mean. Publication bias is suggested by the absence of 
results in one of the parts of the “funnel” (eg, lower right corner 
in   Figure 3  , where small null studies would be plotted). Formal 
testing of publication bias is helpful, but keeping the bandwagon 
effect concept in mind would go a long way to instilling skepticism 
when assessing the strength of evidence provided by a new report 
on a popular hypothesis.           
    Caveats and Conclusions 
  The examples presented in this commentary suggest that false-
  positive results are a common problem in cancer and other types of 
epidemiological studies. What can be done within the practice of 
epidemiology to reduce the problem? One of the simplest yet 
potentially most effective remedies involves increasing emphasis on 
skepticism when assessing study results, particularly when they are 
new. Put another way, epidemiologists should practice some epis-
temological modesty when interpreting and presenting their find-
ings. Epidemiologists by training are most often aware of the 
methodological limitations of observational studies, particularly 
those done by others, yet when it comes to practice, and especially 
the interpretation of their own study results, methodological vigi-
lance is often absent. This absence of skepticism in reporting results 
in published papers increases the likelihood that a positive finding 
will receive unwarranted attention in the media and by the public. 
  The tendency to emphasize and overinterpret what appear to be 
new ﬁ  ndings is commonplace, perhaps in part because of a belief that 
the ﬁ  ndings provide information that may ultimately improve public 
health. Although the results may turn out to be wrong, some authors 
feel it is better to err on the side of overreporting or overstating 
potentially false-positive results than to miss the identiﬁ  cation of a 
potential new hazard or an opportunity for career advancement. 
This tendency to hype new ﬁ   ndings increases the likelihood of 
downplaying inconsistencies within the data or any lack of concor-
dance with other sources of evidence. Furthermore, the clear 
acknowledgement that the statistically signiﬁ  cant ﬁ  ndings may arise 
from multiple comparisons or subgroup analyses is often missing; 
results from a single study are often dispersed across multiple publi-
cations, sometimes without reference to each other, hindering the 
detection of the multiple comparisons or subgroup reporting. 
  Strict adherence to the highest epidemiological standards in the 
design, analysis, reporting, and interpretation of studies would help 
reduce the likelihood and impact of false-positive results. These 
standards include provisions to reduce the opportunity for bias and 
confounding in study design, adequate statistical power, avoidance 
(or at least cautious interpretation) of data-driven subgroup analy-
ses, and accounting for multiple comparisons. The strategy for 
reporting study results should be speciﬁ  ed before the results are 
known, and selective reporting or emphasis of statistically signiﬁ  cant 
results based on ex post facto subgroup analyses should be discour-
aged. The interpretation of positive results, especially if they are not 
supported by additional evidence (eg, other epidemiological or 
experimental studies), should be careful and cautious. These consid-
erations are particularly important in the summary and abstract of 
published papers. They are also in line with many of the recom-
mendations in the Strengthening the Reporting of Observational 
studies in Epidemiology (STROBE) statement, which is aimed at 
strengthening the reporting of epidemiological studies (  77  ,  78  ). We 
propose that the policies of some journals, which require the explicit 
acknowledgement of study limitations up front in the abstract or in 
a note box, become standard practice. Caution should be applied in 
the communication of results to the media and the general public, 
because “positive” ﬁ  ndings tend to attract the media and public 
attention, whereas ﬁ   ndings that do not conﬁ   rm a previously 
reported association or do not indicate a new association often 
receive no attention. Consequently, false-positive results tend to 
survive longer and have larger long-term consequences in the gen-
eral public than in the scientiﬁ  c community. Likewise, users of epi-
demiological results outside the scientiﬁ  c community (eg, regulatory 
agencies, stakeholders, media, advocacy groups, trial lawyers, the 
general public) should be aware of the fact that statistically signiﬁ  -
cant or positive results are often false, in particular when they are 
not supported by related studies or other lines of evidence. 
  The examples we have presented in this commentary were 
restricted largely to the ﬁ  eld of cancer epidemiology. However, we 
believe that similar problems affect other areas of epidemiological 
research, in particular those involving studies with large sets of 
“determinant” and “outcome” variables. A careful analysis of fac-
tors enhancing the likelihood of false-positive reporting should be 
part of the training of epidemiologists, and these issues should be 
addressed in the “Discussion” section of every epidemiological 
paper. In general, epidemiologists should recognize the reporting 
of false-positive results as a major challenge to the scientiﬁ  c credi-
bility of their discipline and institutionalize a greater level of epis-
temological modesty in this regard (  4  ,  79  ).       
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